Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.10 USD
Change Today -0.0199 / -16.58%
Volume 15.7K
ISLT On Other Exchanges
As of 8:10 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

islet sciences inc (ISLT) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/10/14 - $0.39
52 Week Low
12/17/14 - $0.09
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ISLET SCIENCES INC (ISLT)

Related News

No related news articles were found.

islet sciences inc (ISLT) Related Businessweek News

No Related Businessweek News Found

islet sciences inc (ISLT) Details

Islet Sciences, Inc., a biotechnology company, is engaged in the research, development, and commercialization of new medicines and technologies for the treatment of metabolic diseases and related indications covering unmet medical needs. The company offers ISLT-P, an implantable suspension of encapsulated insulin-producing porcine islet cells for the treatment of insulin-dependent diabetes; ISLT-2669, a novel lead IL-12 small molecule inhibitor selected for preclinical development for treatment of type 2 diabetes; and ISLT-LSF Analogs, a library of small molecule lisofylline analogs that block inflammatory actions of cytokines, which destroy insulin-producing beta cells for diabetes and diabetes-related complications. It is also involved in developing ISLT-Bdx, a PCR based molecular diagnostic measuring hypomethylated beta cell-derived DNA as a biomarker of beta cell loss for the early detection of type 1 diabetes or onset of insulin dependent type 2 diabetes. In addition, the company develops Remogliflozin, a selective SGLT2 inhibitor in Phase II clinical development for type 2 diabetes and nonalcoholic steatohepatitis. Islet Sciences, Inc. was founded in 2010 and is based in Raleigh, North Carolina.

3 Employees
Last Reported Date: 07/28/14
Founded in 2010

islet sciences inc (ISLT) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $75.0K
Chief Operating Officer, Director and Chairma...
Total Annual Compensation: $75.0K
Compensation as of Fiscal Year 2014.

islet sciences inc (ISLT) Key Developments

Islet Sciences, Inc. Publishes Data Supporting Remogliflozin Etabonate as a Potential Treatment for NAFLD and NASH

Islet Sciences, Inc. has announced publication of pre-clinical data that demonstrates remogliflozin etabonate has significant potential as a novel therapeutic for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Data published in the Journal of Clinical and Experimental Hepatology show that treatment with remogliflozin etabonate for four weeks in a mouse model of NAFLD inhibited high fat diet-induced weight gain, reduced fat accumulation in the liver, and reduced serum alanine aminotransferase and aspartate aminotransferase to normal or near normal levels. In addition, remogliflozin etabonate treated animals displayed decreased inflammation in the liver, as well as lower oxidative stress. Data from this study also showed that remogliflozin has significant intrinsic anti-oxidant activity. These data along with published clinical data showing remogliflozin etabonate's ability to improve insulin sensitivity, reduce weight and lower elevated liver enzymes, strongly suggest remogliflozin etabonate as a possible therapeutic for NAFLD/NASH.

Islet Sciences, Inc. Announces Board Changes

On April 24, 2015, Dr. James Snapper was appointed as a director of Islet Sciences, Inc. Dr. Snapper is currently a Professor of Medicine at the Duke University School of Medicine, has extensive experience in the pharmaceutical industry and is an internationally recognized expert in the field of translational medicine. Jim is the recipient of many NIH grants and author of numerous scientific publications. On April 24, 2015, Larry Hutchison was appointed as a director of the company. Mr. Hutchison is currently president and CEO of Petrobeam. Mr. Hutchison is also a principal of TA Capital Ltd. Larry spent 35 years at United Parcel Service of America (UPS) in various roles of increasing responsibility. During that time Mr. Hutchison was responsible for various domestic and international operations, including UPS's expansion into the European Union. On April 24, 2015, Antonio O'Ferral was appointed as a director of the company. Mr. O'Ferral has over 15 years of commercial experience in the pharmaceutical, biotechnology and medical device industry with a focus on diabetes and metabolic disease. Mr. O'Ferral is currently in a senior sales manager role at Asante Solutions, Inc. where he is responsible for commercial strategy and sales for the snap insulin pump. Antonio is also on the board and vice president of Outreach at the Triangle Chapter of the Juvenile Diabetes Research Foundation (JDRF). Prior to Asante, Antonio held various positions of increasing responsibility at Insulet and Eli Lilly. On March 18, 2015, Joel Perlin, a member of the company’s Board of Directors and the Avogenx, Inc. Board of Directors, resigned from each Board to devote time to other matters. Mr. Perlin's resignation was not the result of any disagreement with the company on any matter relating to the company's operations, policies or practices. Mr. Perlin was on the audit, compensation, and nominating committees. On March 26, 2015, Dr. Michael Luther, a member of the company’s board of directors and the Avogenx, Inc. board of directors, resigned from each Board. In his resignation letter, Dr. Luther stated he did not have the time required to contribute as a board member to ensure that Islet achieves its goals. Mr. Luther's resignation was not the result of any disagreement with the company on any matter relating to the company's operations, policies or practices. Dr. Luther was the chairman of the compensation committee.

Islet Sciences, Inc. COO to Present at EASL: Remogliflozin Etabonate as Novel Treatment for Non-Alcoholic Steatohepatitis (NASH)

Islet Sciences, Inc. announced that Chief Operating Officer, Dr. William Wilkison, was invited to present clinical and preclinical data highlighting the unique properties of selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate, as a novel treatment for non-alcoholic steatohepatitis (NASH) and its precursor, non-alcoholic fatty liver disease (NAFLD). The data will be presented at the 50th International Liver Conference held in Vienna, Austria April 22 26, 2015 by the European Association for the Study of Liver (EASL). The etiology of non-alcoholic steatohepatitis (NASH) is due, in part, to a combination of insulin resistance and oxidative stress. To date, studies with anti-diabetics or anti-oxidants have resulted in small effects on reversal of these factors in NASH patients. Remogliflozin etabonate (Remo) is an SGLT2 inhibitor shown to reduce HbA1c, improve insulin sensitivity and beta cell function, as well as reduce adiposity and body weight in type 2 diabetics. Additionally, unlike other SGLT2 inhibitors, Remo demonstrates intrinsic anti-oxidant activity, which may reverse the steatohepatitis and oxidative stress required to progress and maintain NASH. Remo is expected to enter phase 2b for NASH in 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISLT:US $0.10 USD -0.0199

ISLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ISLT.
View Industry Companies

Industry Analysis


Industry Average

Valuation ISLT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISLET SCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at